JP2010525025A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525025A5
JP2010525025A5 JP2010504692A JP2010504692A JP2010525025A5 JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5 JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5
Authority
JP
Japan
Prior art keywords
phenyl
compound
pyrimidin
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525025A (ja
JP5566880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/055017 external-priority patent/WO2008129080A1/en
Publication of JP2010525025A publication Critical patent/JP2010525025A/ja
Publication of JP2010525025A5 publication Critical patent/JP2010525025A5/ja
Application granted granted Critical
Publication of JP5566880B2 publication Critical patent/JP5566880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504692A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体 Expired - Fee Related JP5566880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2007003608 2007-04-24
EPPCT/EP2007/003608 2007-04-24
EP07106951.2 2007-04-25
EP07106951 2007-04-25
PCT/EP2008/055017 WO2008129080A1 (en) 2007-04-24 2008-04-24 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2010525025A JP2010525025A (ja) 2010-07-22
JP2010525025A5 true JP2010525025A5 (enExample) 2011-06-23
JP5566880B2 JP5566880B2 (ja) 2014-08-06

Family

ID=39745232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504692A Expired - Fee Related JP5566880B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体

Country Status (4)

Country Link
US (2) US8507498B2 (enExample)
EP (1) EP2137166B1 (enExample)
JP (1) JP5566880B2 (enExample)
WO (1) WO2008129080A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
CN102933561B (zh) * 2010-03-22 2016-05-11 利德发现中心有限责任公司 具有药学活性的二取代三嗪衍生物
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
JP5947818B2 (ja) * 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
CA2833288A1 (en) 2011-04-19 2012-10-26 Bayer Intellectual Property Gmbh Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2755956B1 (en) * 2011-09-16 2016-05-18 Bayer Intellectual Property GmbH 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors
JP5976814B2 (ja) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH スルホキシイミン基を含有する二置換5−フルオロピリミジン誘導体
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
ES2661717T3 (es) * 2012-08-23 2018-04-03 Virostatics Srl Derivados de aminopirimidina 4,6-disustituidos novedosos
CA2888381A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CA2888383A1 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
ES2595222T3 (es) 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
SG11201503079PA (en) 2012-11-15 2015-06-29 Bayer Pharma AG 5-FLUORO-<i>N</i>-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP
TW201418243A (zh) * 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
CA2891244C (en) * 2012-11-15 2020-12-01 Ulrich Lucking 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
CA2917096C (en) 2013-07-04 2021-05-18 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
CN105764511B (zh) 2013-10-04 2019-01-11 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
CA2944727A1 (en) 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
CN106459084B (zh) 2014-04-11 2019-04-19 拜耳医药股份有限公司 大环化合物
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
EP3207037B1 (en) 2014-10-16 2019-01-23 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
CA2964696C (en) 2014-10-16 2022-09-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
WO2016150893A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
WO2016150903A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
DK3539961T3 (da) 2015-06-29 2022-01-03 Astrazeneca Ab Polycykliske amidderivativer som cdk9-inhibitorer
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20180015153A1 (en) 2016-07-16 2018-01-18 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
WO2019075011A1 (en) 2017-10-10 2019-04-18 Florida State University Research Foundation, Inc. EMETIC COMPOUNDS FOR THE TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION
JP2021501203A (ja) 2017-10-30 2021-01-14 アプトース バイオサイエンシズ インコーポレイテッド がん治療用のアリールイミダゾール
CN111727183B (zh) 2018-02-13 2023-12-29 拜耳公司 5-氟-4-(4-氟-2-甲氧基苯基)-n-{4-[(s-甲基磺亚胺酰基)甲基]吡啶-2-基}吡啶-2-胺用于治疗弥漫性大b细胞淋巴瘤中的用途
WO2020235672A1 (ja) * 2019-05-23 2020-11-26 国立大学法人京都大学 アルツハイマー病のための医薬組成物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040106647A1 (en) 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
AU2003285007A1 (en) 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain
EP2137165B1 (en) * 2007-04-24 2013-04-24 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
WO2008129070A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP5566879B2 (ja) * 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤

Similar Documents

Publication Publication Date Title
JP2010525025A5 (enExample)
JP2011502956A5 (enExample)
JP2004536814A5 (enExample)
JP2021504443A5 (enExample)
RU2412937C2 (ru) Соединения трехзамещенного амина и их применение в качестве ингибиторов белка переноса холестерилового эфира (сетр)
JP2013523710A5 (enExample)
HRP20241159T1 (hr) Heterociklički agonisti za glp-1
RU2013148405A (ru) Ингибиторы киназ
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
RU2006146985A (ru) Модуляторы мускариновых рецепторов
HUT67636A (en) New sulfonylamino-pyrimidines and pharmaceutical compositions containing them
JP2009541268A5 (enExample)
JP2020529405A5 (enExample)
IL172567A (en) Trisubstituted aryl and heteroaryl derivatives, pharmaceutical compositions comprising them and their use in the preparation of medicaments for the prophylaxis and treatment of disorders related to metabolism
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2011519854A5 (enExample)
JP2013523803A5 (enExample)
JP2016512844A5 (enExample)
JP2011523646A5 (enExample)
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
JP2007500179A5 (enExample)
JP2017515836A5 (enExample)
ME02763B (me) Derivati bipirazola kao inhibitori jak
RU2009133846A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ
JP2010535824A (ja) Dhodh阻害剤としてのアザビフェニルアミノ安息香酸誘導体